Abeona Therapeutics Inc (NASDAQ:ABEO) CEO Vishwas Seshadri Sells 25,000 Shares

Abeona Therapeutics Inc (NASDAQ:ABEO) CEO Vishwas Seshadri sold 25,000 shares of the stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $4.78, for a total transaction of $119,500.00. Following the sale, the chief executive officer now directly owns 1,355,322 shares of the company’s stock, valued at approximately $6,478,439.16. This represents a 1.81 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Abeona Therapeutics Stock Performance

Shares of Abeona Therapeutics stock opened at $4.76 on Tuesday. The business has a fifty day simple moving average of $5.41 and a 200-day simple moving average of $5.81. Abeona Therapeutics Inc has a 12 month low of $3.05 and a 12 month high of $8.45. The stock has a market cap of $231.02 million, a PE ratio of -1.77 and a beta of 1.79. The company has a quick ratio of 6.12, a current ratio of 6.12 and a debt-to-equity ratio of 0.31.

Abeona Therapeutics (NASDAQ:ABEO) last issued its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.19. On average, sell-side analysts anticipate that Abeona Therapeutics Inc will post -1.16 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of ABEO. Twinbeech Capital LP acquired a new stake in shares of Abeona Therapeutics during the 4th quarter valued at about $58,000. Northern Trust Corp lifted its stake in shares of Abeona Therapeutics by 6.6% in the 4th quarter. Northern Trust Corp now owns 184,929 shares of the biopharmaceutical company’s stock valued at $1,030,000 after purchasing an additional 11,478 shares during the last quarter. Squarepoint Ops LLC bought a new stake in Abeona Therapeutics in the fourth quarter worth $67,000. Jane Street Group LLC acquired a new position in Abeona Therapeutics during the third quarter worth $84,000. Finally, Oxford Asset Management LLP bought a new position in Abeona Therapeutics during the fourth quarter valued at about $118,000. 80.56% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ABEO has been the subject of several research reports. Oppenheimer assumed coverage on Abeona Therapeutics in a research note on Wednesday, March 5th. They set an “outperform” rating and a $16.00 price objective for the company. HC Wainwright reiterated a “buy” rating and issued a $15.00 price target on shares of Abeona Therapeutics in a research report on Monday, March 24th. Finally, StockNews.com upgraded Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, March 24th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, Abeona Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $17.50.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.